Beta Blockers and Angiotensin Receptor Blockers in Bicuspid Aortic Valve Disease Aortopathy (BAV Study)

Summary

The purpose of this study is to determine whether long-term treatment with a beta-blocker (BB) such as atenolol and/or an angiotensin receptor blocker (ARB) such as telmisartan, given to adult patients with bicuspid aortic valve (BAV) disease (aortopathy) reduces the widening (dilatation) of the aorta from its baseline size.

Timeline

Start

2011-06

Primary completion

2016-04-19

Completion

2016-11

Outcome

Outcome not reported

Stopped (Enrollment): “Terminated early due to lack of study feasibility and poor patient recruitment”

Drugs

Indications